IL6 and congenital rubella syndrome: In a clinical study involving 74 patients treated with CAR T cell therapy, the incidence of grade ≥ 3 CRS after CAR T cell infusion was 56% in patients with an IL-6 level of ≥ 40 pg/mL, and the mortality rate of these patients within 90 days was as high as 89%70.